

Listing of Claims

1. (Canceled).
2. (Canceled).
3. (Canceled).
4. (Canceled).
5. (Canceled).
6. (Canceled).
7. (Canceled).
8. (Canceled).
9. (Currently amended) A method ~~to use the pharmaceutical composition in~~
any one of claims 1-4 or 11 for reduction of plasma glucose
concentrations in treating diseases, disorders or conditions in human or
non-human mammals, said method comprising the step of administration
of a pharmaceutical composition to said human or said non-human
mammals, wherein said pharmaceutical composition consists of, as active
agent, (1) a glucose-lowering agent metformin in one of its
pharmaceutically acceptable forms, and (2) a lipid-improving agent
selected from non-glucose-lowering fibrates, wherein said diseases,
disorders or conditions are selected from the group consisting of diabetes
mellitus, hyperglycemia, impaired glucose-tolerance, insulin resistant
syndrome, obesity, and pancreatitis ~~and other disorders~~ where
abnormality in plasma glucose levels or glucose metabolism is a

~~component, comprising the administration of the said composition to
human or non-human mammals.~~

10. (Original) The method according to claim 9, wherein the administration is by means of oral, inhalation, sublingual, buccal, intranasal, rectal, intravenous, subcutaneous, intramuscular, and transdermal administration.
11. (Currently amended) ~~The pharmaceutical composition according to claim 3, method of claim 13, wherein~~ characterized by weight ratio of metformin or of its pharmaceutically acceptable form to gemfibrozil ranges from 1:0.5 to 1:2.
12. (New) The method of claim 9, wherein the non-glucose-lowering fibrate is selected from gemfibrozil and ciprofibrate.
13. (New) The method of claim 12, wherein the non-glucose-lowering fibrate is gemfibrozil.
14. (New) The method of claim 9, wherein the glucose-lowering agent and the lipid-improving agent are mixed together to form an admixture and the admixture is administered to the human or non-human mammals.